Ocrelizumab for treating relapsing multiple sclerosis
Ocrelizumab for treating relapsing multiple sclerosis
This report is a critique of the company’s submission (CS) to NICE from Roche on the clinical effectiveness and cost effectiveness of ocrelizumab for relapsing forms of multiple sclerosis. It identifies the strengths and weaknesses of the CS.
National Institute for Health and Care Research
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Onyimadu, Oluchukwu
ff168bd7-1c4f-4756-a34a-7e6b930ae29b
Harris, Petra B
a8bd143b-3e2c-4929-9279-510a4c60bd09
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Frampton, Geoffrey
26c6163c-3428-45b8-b8b9-92091ff6c69f
8 May 2018
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Onyimadu, Oluchukwu
ff168bd7-1c4f-4756-a34a-7e6b930ae29b
Harris, Petra B
a8bd143b-3e2c-4929-9279-510a4c60bd09
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Frampton, Geoffrey
26c6163c-3428-45b8-b8b9-92091ff6c69f
Lord, Joanne, Onyimadu, Oluchukwu, Harris, Petra B, Shepherd, Jonathan and Frampton, Geoffrey
(2018)
Ocrelizumab for treating relapsing multiple sclerosis
(Health Technology Assessment, HTA - 16/56/24)
Southampton.
National Institute for Health and Care Research
194pp.
Record type:
Monograph
(Project Report)
Abstract
This report is a critique of the company’s submission (CS) to NICE from Roche on the clinical effectiveness and cost effectiveness of ocrelizumab for relapsing forms of multiple sclerosis. It identifies the strengths and weaknesses of the CS.
Text
Ocrelizumab ERG Report
More information
Published date: 8 May 2018
Identifiers
Local EPrints ID: 438090
URI: http://eprints.soton.ac.uk/id/eprint/438090
PURE UUID: 3751460e-e5fe-48fe-a670-62d14475e907
Catalogue record
Date deposited: 28 Feb 2020 17:31
Last modified: 11 Sep 2024 02:04
Export record
Contributors
Author:
Petra B Harris
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics